Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis
A live, multi-source view of Recursion Pharmaceuticals, Inc. (RXRX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 600 employees · recursion.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Recursion Pharmaceuticals, Inc. (RXRX) had a market capitalization of $1.95B (forward -4.1) and a beta of 1.07; the shares traded in a 52-week range of $2.77 – $7.18 (-21.4% over the year).
- Market cap
- $1.95B
- Enterprise value
- $1.46B
- Forward P/E
- -4.1
- Price / book
- 2.12
- EPS (trailing)
- $-1.06
- EPS (forward)
- $-0.89
- Payout ratio
- 0.0%
- 52-week range
- $2.77 – $7.18
- 52-week change
- -21.4%
- Beta
- 1.07
- Average volume
- 19.2M
- Shares outstanding
- 535.3M
- Short % of float
- 34.79%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Recursion Pharmaceuticals, Inc. (RXRX) last closed at $3.16 (the last completed close before that scan).
Technicals at the scan: RSI 45 (neutral territory), price -5.7% versus its 20-day average, 20-day versus 50-day average spread +1.2%, MACD histogram -0.02.
Sentiment inputs: 0% of recent Finnhub-scored headlines read bullish; StockTwits 60% bullish; Reddit mentions 0% over 24 hours; analyst consensus score 68/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RXRX; corporate insiders filed 0 buys and 3 sells (2 distinct filers, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Blake Borgeson (0B/2S), Najat Khan (0B/1S). Who is trading what
RapidTradeView pick record
RXRX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Recursion Pharmaceuticals, Inc. (RXRX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RXRX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.